<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00825747</url>
  </required_header>
  <id_info>
    <org_study_id>SeeLensAF 65</org_study_id>
    <nct_id>NCT00825747</nct_id>
  </id_info>
  <brief_title>Evaluation of Seelens AF, an Aspheric Intra-ocular Lens</brief_title>
  <official_title>Clinical Evaluation of the Aspheric SeeLens AF Intra-ocular Lens.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanita Lenses</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanita Lenses</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Senile cataract is managed by cataract extraction and intra-ocular lens (IOL) implantation.&#xD;
      The purpose of this study is to evaluate the safety and efficacy of the SeeLens AF, an&#xD;
      acrylic hydrophilic aspheric IOL. This lens was designed to reduce vision aberrations and&#xD;
      secondary cataract formation rate.&#xD;
&#xD;
      Preoperative evaluation: Best corrected visual acuity, refraction, comprehensive slit lamp&#xD;
      examination and biometry.&#xD;
&#xD;
      Surgical procedure: Cataract surgery using a clear corneal incision (1.8mm to2.4mm),&#xD;
      phacoemulsification and implantation of the SeeLens AF to the capsular bag. IOL implantation&#xD;
      parameters will be evaluated by the surgeon.&#xD;
&#xD;
      Postoperative follow up: Best corrected visual acuity, uncorrected visual acuity, refraction&#xD;
      and comprehensive slit lamp examinations up to 3 months after surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    study was closed&#xD;
  </why_stopped>
  <start_date type="Actual">January 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity 3 months after SeeLens AF implantation</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications related to SeeLens AF implantation during cataract surgery.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative severe intra-ocular inflammation or infection</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction of ocular refraction after cataract surgery with Seelens AF implantation</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Cataract</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SeeLens AF intra-ocular lens</intervention_name>
    <description>the SeeLens AF is an acrylic hydrophilic C shaped haptics intra-ocular lens, designed for implantation in the lenticular capsular bag or the sulcus during cataract surgery.</description>
    <other_name>aspheric SeeLens</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Senile Cataract&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Cataract extraction using phacoemulsification&#xD;
&#xD;
          -  Corneal incision less than 1.5 mm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy/sensitivity to eye drops used during and after cataract surgery&#xD;
&#xD;
          -  Amblyopia/ strabismus&#xD;
&#xD;
          -  Ocular disease, other than cataract, diminishing visual acuity, such as corneal&#xD;
             opacity, advanced glaucoma, diabetic retinopathy, exudative or moderate to severe&#xD;
             non-exudative age-related macular degeneration, uveitis.&#xD;
&#xD;
          -  previous ocular surgery or ocular trauma in the investigated eye&#xD;
&#xD;
          -  Ocular anomaly, such as microphthalmos&#xD;
&#xD;
          -  Keratometry values less than 40 diopters or more than 47 diopters.&#xD;
&#xD;
          -  Ocular axial length less than 21.0 mm or longer than 25.0 mm&#xD;
&#xD;
          -  Intra-operative complications prior to intraocular lens implantation, such as tear of&#xD;
             the posterior capsule.&#xD;
&#xD;
          -  posterior capsular scar&#xD;
&#xD;
          -  visual acuity in the fellow eye less than 20/200&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yokrat Ton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meir Medical Center, affiliated with Tel-Aviv University, Tel-Aviv, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44410</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 18, 2009</study_first_submitted>
  <study_first_submitted_qc>January 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2009</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <name_title>Simha Siboni, regulatory manager</name_title>
    <organization>Hanita Lenses, Israel</organization>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Cataract surgery</keyword>
  <keyword>intraocular lens</keyword>
  <keyword>Aspheric lens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

